Skip to main content
OpenTrials

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,034 public trials 567 recruiting studies
Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Recruiting

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

NCT07454187

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital Of Soochow University Suzhou, Jiangsu, China
  • The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital) Xi’an, Shanxi, China
  • The Second Affiliated Hospital Zhejiang University School Of Medicine Hangzhou, Zhejiang, China
View Trial Details
Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

NCT05714839

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • GSK Investigational Site Bullhead City, Arizona, United States
  • GSK Investigational Site Pembroke Pines, Florida, United States
  • GSK Investigational Site Grand Rapids, Michigan, United States
  • GSK Investigational Site Chapel Hill, North Carolina, United States
View all 36 locations
View Trial Details
Recruiting

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

NCT06508983

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beijing Chaoyang Hospital of Capital Medical University Beijing, Beijing Municipality, China
  • Guangzhou First People's Hospital Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • First Affiliated Hospital of Henan University of Science and Technology Luoyang, Henan, China
View Trial Details
Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Infirmary Cancer Care Mobile, Alabama, United States
  • Western Regional Medical Center, Inc. dba. City of Hope Phoenix Goodyear, Arizona, United States
  • Beverly Hills Cancer Center Beverly Hills, California, United States
  • Clovis Community Medical Center Clovis, California, United States
View all 271 locations
View Trial Details
Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Jupiter Medical Center/Anderson Family Cancer Institute Jupiter, Florida, United States
  • MSK Basking Ridge Basking Ridge, New Jersey, United States
  • MSK Monmouth Middletown, New Jersey, United States
  • MSK Bergen Montvale, New Jersey, United States
View all 127 locations
View Trial Details
Recruiting

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT07455851

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Prince of Wales Hospital Randwick, New South Wales, Australia
  • Illawarra Cancer care centre, Wollongong Hospital Wollongong, New South Wales, Australia
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Peter MacCallum Cancer Centre Melbourne, Victoria, Australia
View Trial Details
Recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

NCT06140524

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations
  • Johns Hopkins Hospital Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Michigan Health Ann Arbor, Michigan, United States
  • NYU Langone Health Perlmutter Cancer Center New York, United States
View all 39 locations
View Trial Details
Recruiting

Mosaic Trial for Stem Cell Transplant Recipients

NCT06960993

Conditions
Blood Protein Disorders, Bone Marrow Diseases, Bone Marrow Transplant, +22 more
Locations
  • Georgetown University School of Medicine Washington D.C., District of Columbia, United States
  • Northwestern University Feinberg School of Medicine Chicago, Illinois, United States
  • Hackensack Meridian Health Nutley, New Jersey, United States
View Trial Details

Related conditions